AUTHORS
Sikander Ailawadhi, MD, Nicole Niehoff, PhD, MPH2, Natalie Boytsov, PhD3, Teresa Palumbo, DMSc, PA-C4, Kelly Brock, PharmD5, Molly Purser, PhD6, Abigail Herbst7, Bridget Gaglio8, Daniel Bretton9, Martin Parkinson10, Natasha Edwin, MD11
AFFILIATIONS
1 Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, United States
2 GSK, Durham, NC, United States
3 GSK, Upper Providence, PA, United States
4 GSK, New York, NY, United States
5 GSK, Durham, NC, United States
6 GSK, Upper Providence, PA, United States
7 PPD Evidera Solutions, a part of Thermo Fisher Scientific, Waltham, MA, United States
8 PPD Evidera Solutions, a part of Thermo Fisher Scientific, Waltham, MA, United States
9 PPD Evidera Solutions, a part of Thermo Fisher Scientific, London, United Kingdom
10 PPD Evidera Solutions, a part of Thermo Fisher Scientific, London, United Kingdom
11 Providence Cancer Center Oncology and Hematology Care Clinic, Portland, OR, United States
ABSTRACT
Introduction: B-cell maturation antigen (BCMA) is an effective target for MM, with BCMA-targeting therapies (CAR-T, bispecific antibodies, and an antibody-drug conjugate) producing substantial benefits in response rates and durability vs standard-of-care (SoC) triplets. Despite high efficacy, feasibility of tx delivery across all sites of care remains an important consideration. This study evaluated logistical, accessibility, and tx experience barriers reported by HCPs who prescribe/manage CAR-T, and by pts who were prescribed CAR-T across AC and CC.
Methods: A one-time, cross-sectional, web-based survey of US HCPs and pts from AC and CC was conducted (March–April 2026). HCPs experienced with managing/prescribing CAR-T were eligible. Pts with MM prescribed CAR-T within the past year were eligible if they either received, did not respond to, or had not yet received CAR-T. Surveys were available in English and Spanish (pts only), and pts provided consent. The HCP survey captured characteristics, prescribing/management experience, logistical/practical issues, and impacts of tx on pts/HCPs. The pt survey captured demographics, pt experience, use of, and barriers to CAR-T. Questions were multiple choice or rated from 1 (not at all important) to 5 (extremely important), and data were analyzed descriptively.
Results: Surveys were completed by 46 HCPs (n=30/16 AC/CC) and 46 pts prescribed CAR-T in the past year (38 started [n=28/10 AC/CC] and 32 [n=25/7] completed CAR-T). HCP MM tx experience varied: n=10 had <5 years (y) experience, n=9 had 6–10 y, and n=27 had >10 y. Overall, each HCP managed a median of 55 pts/y (median 63/50 pts AC/CC). Most pts who completed the survey were ≤64 y (63/92% AC/CC) and identified as White (66/77%) and female (59/39%).
HCPs reported that pt factors (age/frailty/performance status/comorbidities) were key when deciding to prescribe CAR-T (rated extremely important by 63/81% AC/CC). Pt circumstances (ability to travel/take time off work or commitments, caregiver support) were also important factors (rated important or extremely important by 90/81% AC/CC). Disease characteristics were more important for HCPs in CC than AC (27/69% AC/CC, extremely important). CAR-T referral/prescribing were also influenced by complexity of care for 80/75% of HCPs in AC/CC. Care complexity impacted HCP workload before and after CAR-T infusion compared to SoC tx, due to increased cross-specialty communication for coordinated care in AC/CC (before: 73/69%; after: 57/56%) and increased pt monitoring (before: 47/69%; after: 63/75%). Post infusion, HCPs reported increased long term follow-up requirements (60/69% AC/CC). Financial/reimbursement issues (63/69% AC/CC) and complex manufacturing (50/63% AC/CC) were reported as CAR-T access barriers. HCPs restricted the number of pts prescribed CAR-T, particularly due to care planning/administrative hurdles (30/50% AC/CC) and pt context (e.g. insurance type, tx center proximity) (43/25% AC/CC).
Pts who started the CAR-T tx process in AC/CC (n=28/10) reported time to/from appointments (18/40%) and impact on daily life (43/90%) as difficult, particularly in CC. For each CAR-T-related appointment, 25/50% of pts in AC/CC reported >1–<2 hrs of round-trip travel. Financial burden in AC/CC was reported as difficult in 39/30%, and a substantially higher proportion in CC reported the burden as very difficult (7/50%). Support from caregivers (86/90% AC/CC) and transportation support (36/60% AC/CC) were needed during tx. Among pts who completed CAR-T infusion (n=25/7 AC/CC), more in CC than AC needed to stay away from home (48/71%); pts who stayed away from home (n=12/5), reported financial burdens from accommodations (33/60% AC/CC) and travel (25/80% AC/CC). Pts who completed infusion required support from caregivers (92/86% AC/CC) and transportation support (48/71%) during recovery.
Conclusions: BCMA-targeting txs have transformed MM outcomes, but CAR-T access/delivery barriers persist. HCPs associated CAR-T with challenges that increase workload, restricting the number of pts prescribed CAR-T, and prioritizing based on pt factors. Pts reported daily-life, logistical, and financial challenges, particularly for those in CC travelling for care. A BCMA-targeted approach is needed that eases tx delivery, reduces care needs, optimizes accessibility, and ultimately, lowers HCP and pt burden to offer all pts the opportunity for transformational survival benefit with BCMA-directed therapy.
DISCLOSURES
Sikander Ailawadhi, MD: BMS - Research Funding; Xencor - Research Funding; Cellectar - Research Funding; Janssen - Research Funding; Ascentage Pharma Group Inc. - Research Funding; Amgen - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)